Zenas BioPharma (ZBIO) Assets Average (2024 - 2026)

Zenas BioPharma's Assets Average history runs 3 years deep, the most recent figure standing at $565.7 million for Q1 2026.

• On a quarterly basis, Assets Average rose 60.76% year-over-year to $565.7 million in Q1 2026; TTM through Mar 2026 was $565.7 million, a 60.76% increase from a year earlier, with the FY2025 full-year figure at $376.8 million, up 72.0% from the prior year.
• Assets Average climbed to $565.7 million in Q1 2026 per ZBIO's latest filing, from $352.8 million in the prior quarter.
• Across five years, Assets Average topped out at $565.7 million in Q1 2026 and bottomed at $307.6 million in Q3 2025.
• The 3-year median for Assets Average is $352.3 million (2025), against an average of $379.7 million.
• Across the five-year window, Assets Average retreated 8.76% in 2025 and soared 60.76% in 2026, its largest moves.
• Year by year, Assets Average stood at $386.7 million in 2024, then slipped by 8.76% to $352.8 million in 2025, then surged by 60.32% to $565.7 million in 2026.
• Per Business Quant, the three latest ZBIO Assets Average figures stand at $565.7 million (Q1 2026), $352.8 million (Q4 2025), and $307.6 million (Q3 2025).